Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Leukemia through trial conditions or approval indications mapped to it or to one of its descendant entities.
26 drugs · 856 active trials
42 drugs · 1,287 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 3. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Venetoclax | Approved | Phase 4 | 276 | 168 | 62 | 424 | 1 | US | Apr 11, 2016 | Jul 11, 2007 |
| Azacitidine | Approved | Phase 4 | 159 | 92 | 50 | 388 | 2 | EU, US | Sep 1, 2020 | 2000-05 |
| Fludarabine | Approved | Phase 4 | 149 | 80 | 58 | 653 | 1 | US | Apr 28, 2004 | 1994-10 |
| Methotrexate | Approved | Phase 4 | 69 | 36 | 83 | 359 | 9 | EU, US | Aug 10, 1959 | 1986-05 |
| Blinatumomab | Approved | Phase 3 | 69 | 37 | 19 | 104 | 4 | EU, US | Dec 3, 2014 | 2008-01 |
| Decitabine | Approved | Phase 4 | 50 | 25 | 24 | 197 | 2 | EU | Sep 20, 2012 | 1995-08 |
| Obinutuzumab | Approved | Phase 3 | 48 | 23 | 22 | 90 | 1 | US | Nov 1, 2013 | Dec 21, 2009 |
| Busulfan | Approved | Phase 4 | 38 | 15 | 31 | 240 | 1 | US | Jun 26, 1954 | 1987-08 |
| Mercaptopurine | Approved | Phase 4 | 38 | 22 | 55 | 149 | 3 | EU, US | Sep 11, 1953 | 1992-10 |
| Idarubicin | Approved | Phase 4 | 32 | 18 | 42 | 174 | 1 | US | Feb 17, 1997 | 1993-01 |
| Gilteritinib | Approved | Phase 3 | 28 | 22 | 10 | 47 | 2 | EU, US | Nov 28, 2018 | Oct 9, 2013 |
| Pegaspargase | Approved | Phase 4 | 26 | 10 | 37 | 99 | 3 | EU, US | Feb 1, 1994 | 1996-03 |
| Pirtobrutinib | Approved | Phase 4 | 23 | 16 | 8 | 28 | 1 | US | Jan 27, 2023 | Mar 15, 2019 |
| Inotuzumab Ozogamicin | Approved | Phase 4 | 21 | 13 | 4 | 36 | 2 | EU, US | Jun 28, 2017 | 2011-08 |
| Revumenib | Approved | Phase 3 | 20 | 13 | 3 | 24 | 1 | US | Nov 15, 2024 | 2016-11 |
| Ivosidenib | Approved | Phase 3 | 20 | 15 | 3 | 23 | 1 | US | Jul 20, 2018 | Mar 1, 2014 |
| Cladribine | Approved | Phase 4 | 19 | 15 | 6 | 59 | 1 | EU | Apr 14, 2004 | 1994-10 |
| Calaspargase Pegol | Approved | Phase 3 | 18 | 9 | 7 | 21 | 1 | US | Dec 20, 2018 | Jul 21, 2008 |
| Filgrastim | Approved | Phase 4 | 17 | 10 | 24 | 205 | 2 | US | Feb 20, 1991 | 1993-01 |
| Gemtuzumab Ozogamicin | Approved | Phase 4 | 17 | 13 | 17 | 83 | 3 | EU, US | Sep 1, 2017 | 1997-02 |
| Bendamustine | Approved | Phase 4 | 16 | 4 | 22 | 80 | 6 | US | Mar 20, 2008 | 2001-09 |
| Lenalidomide | Approved | Phase 4 | 14 | 7 | 6 | 123 | 1 | US | Dec 27, 2005 | 2004-03 |
| Enasidenib | Approved | Phase 3 | 13 | 8 | 2 | 24 | 1 | US | Aug 1, 2017 | Dec 30, 2015 |
| Ziftomenib | Approved | Phase 3 | 12 | 10 | 1 | 12 | 1 | US | Nov 13, 2025 | Sep 12, 2019 |
| Quizartinib | Approved | Phase 3 | 11 | 7 | 5 | 32 | 2 | EU, US | Jul 20, 2023 | 2007-01 |
| Imatinib | Approved | Phase 4 | 10 | 4 | 26 | 83 | 6 | US | Apr 18, 2003 | Aug 9, 1999 |
| Asciminib | Approved | Phase 3 | 10 | 6 | 4 | 18 | 1 | EU | Aug 25, 2022 | Apr 24, 2014 |
| Nilotinib | Approved | Phase 4 | 9 | 3 | 16 | 75 | 7 | EU, US | Oct 29, 2007 | Jul 13, 2001 |
| Arsenic Trioxide | Approved | Phase 4 | 9 | 4 | 10 | 59 | 5 | EU, US | Sep 25, 2000 | 1997-11 |
| Asparaginase | Approved | Phase 4 | 8 | 3 | 37 | 91 | 1 | EU | Jan 14, 2016 | 1990-01 |
| Olutasidenib | Approved | Phase 4 | 8 | 6 | 0 | 9 | 1 | US | Dec 1, 2022 | Jun 18, 2024 |
| Clofarabine | Approved | Phase 3 | 7 | 5 | 8 | 112 | 2 | EU | May 29, 2006 | 1999-02 |
| Midostaurin | Approved | Phase 3 | 5 | 2 | 6 | 35 | 3 | EU, US | Apr 28, 2017 | Jan 30, 2002 |
| Bosutinib | Approved | Phase 4 | 4 | 2 | 4 | 24 | 3 | EU, US | Sep 4, 2012 | Jan 18, 2006 |
| Treosulfan | Approved | Phase 3 | 4 | 4 | 2 | 17 | 1 | US | Jan 21, 2025 | 2004-03 |
| Imatinib Mesylate | Approved | Phase 4 | 3 | 0 | 9 | 74 | 3 | US | Apr 18, 2003 | May 7, 1993 |
| Alemtuzumab | Approved | Phase 3 | 2 | 0 | 3 | 89 | 2 | EU, US | May 7, 2001 | 2000-01 |
| Obecabtagene Autoleucel | Approved | Phase 2 | 2 | 2 | 0 | 2 | 1 | EU | Jul 17, 2025 | Aug 26, 2025 |
| Pentostatin | Approved | Phase 3 | 1 | 0 | 2 | 24 | 1 | US | Oct 11, 1991 | Sep 6, 1994 |
| Glasdegib | Approved | Phase 3 | 1 | 0 | 3 | 12 | 2 | EU, US | Nov 21, 2018 | Jun 27, 2012 |
| Crisantaspase | Approved | Early Phase 1 | 1 | 1 | 0 | 1 | 1 | EU | Sep 15, 2023 | Oct 22, 2025 |
| Histamine | Approved | Phase 3 | 0 | 0 | 1 | 1 | 1 | EU | Oct 7, 2008 | 1998-07 |
| Cyclophosphamide | Phase 4 | Phase 4 | 174 | 93 | 109 | 725 | 0 | — | — | 1987-08 |
| Cytarabine | Phase 4 | Phase 4 | 151 | 83 | 151 | 766 | 0 | — | — | 1986-11 |
| Dexamethasone | Phase 4 | Phase 4 | 67 | 38 | 58 | 232 | 0 | — | — | 1990-01 |
| Rituximab | Phase 4 | Phase 4 | 61 | 30 | 44 | 307 | 0 | — | — | 1997-09 |
| Daunorubicin | Phase 4 | Phase 4 | 55 | 33 | 79 | 232 | 0 | — | — | 1986-11 |
| Vincristine | Phase 4 | Phase 4 | 55 | 28 | 56 | 228 | 0 | — | — | 1990-01 |
| Ibrutinib | Phase 4 | Phase 4 | 34 | 8 | 22 | 109 | 0 | — | — | 2009-02 |
| Acalabrutinib | Phase 4 | Phase 4 | 33 | 18 | 11 | 46 | 0 | — | — | Jan 30, 2014 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.